Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Vomizole 40mg powder for injection

Dexa Medica

Ingredients in every vial

Pantoprazole 40 mg

Each package contains

1 vial of 40 mg

Dosage form

Powder for injection

Dosage formPowder for injection

Flavour

None

W.H.O. classification

A02B
A02B

A.T.C. Level 1

Anatomical Main group

A - Alimentary tract and metabolism
A02B

A.T.C. Level 2

Therapeutic subgroup

A02 - Drugs for Acid Related Disorders
A02B

A.T.C. Level 3

Pharmacological subgroup

A02B - Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Indication

Duodenal ulcer
Gastric ulcer
Reflux esophagitis
Moderate and severe cases of inflammation of the esophagus (reflux esophagitis)
Zollinger-Ellison syndrome

Dosage

0 TO 18 YEARS OLD
Safety and efficacy in children have not been established.

18 TO 65 YEARS OLD
The intravenous administration is recommended
only if oral application is not appropriate.

Duodenal ulcer, gastric ulcer, reflux esophagitis:
The recommended intravenous dosage is one vial (40 mg pantoprazole) per day.

Zollinger-Ellison syndrome & other pathological hypersecretory conditions:
Patients should start their treatment with a daily dose of 80 mg pantoprazole IV. Thereafter, the dosage can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dosage above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control. Transition from oral to IV and from IV to oral formulations of gastric acid inhibitors should be performed in such manner to ensure continuity of effect of suppression of acid secretion.

65 YEARS OLD AND ABOVE
The daily dose of 40 mg pantoprazole should not be exceeded in elderly patients

PATIENTS WITH IMPAIRED RENAL FUNCTION
The daily dose of 40 mg pantoprazole should not be exceeded in patients with impaired renal function.

PATIENTS WITH SEVERE LIVER IMPAIRMENT
In patients with severe liver impairment the daily dose has to be reduced to 20 mg pantoprazole. Furthermore, in these patients the liver enzymes should be monitored during pantoprazole IV therapy. In case of a rise of the liver enzymes pantoprazole IV should be discontinued.